HC Wainwright Cuts Earnings Estimates for Sanara MedTech

Sanara MedTech Inc. (NASDAQ:SMTI) – Stock analysts at HC Wainwright dropped their Q1 2026 earnings per share estimates for shares of Sanara MedTech in a research note issued on Monday, January 26th. HC Wainwright analyst Y. Chen now forecasts that the company will earn $0.13 per share for the quarter, down from their previous estimate of $0.15. HC Wainwright has a “Buy” rating and a $36.00 price target on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Sanara MedTech’s Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.17 EPS, Q4 2026 earnings at $0.19 EPS and FY2026 earnings at $0.65 EPS.

Sanara MedTech (NASDAQ:SMTI) last posted its quarterly earnings results on Wednesday, November 12th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.33. Sanara MedTech had a negative return on equity of 21.33% and a negative net margin of 36.79%.The firm had revenue of $26.33 million during the quarter, compared to analysts’ expectations of $26.63 million.

Other equities research analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Sanara MedTech from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. Zacks Research downgraded Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sanara MedTech in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $41.00.

Sanara MedTech Stock Down 1.5%

SMTI opened at $21.06 on Wednesday. The stock has a market capitalization of $187.43 million, a price-to-earnings ratio of -4.99 and a beta of 1.06. The firm has a 50 day moving average price of $22.92 and a 200-day moving average price of $27.14. Sanara MedTech has a twelve month low of $18.90 and a twelve month high of $37.50. The company has a quick ratio of 1.60, a current ratio of 1.80 and a debt-to-equity ratio of 7.34.

Institutional Trading of Sanara MedTech

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets raised its stake in shares of Sanara MedTech by 351.7% in the third quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company’s stock worth $48,000 after buying an additional 1,171 shares during the period. Lazard Asset Management LLC increased its holdings in Sanara MedTech by 63,100.0% in the 2nd quarter. Lazard Asset Management LLC now owns 3,160 shares of the company’s stock worth $89,000 after acquiring an additional 3,155 shares in the last quarter. Bank of America Corp DE raised its stake in Sanara MedTech by 44.1% during the 3rd quarter. Bank of America Corp DE now owns 3,181 shares of the company’s stock worth $101,000 after acquiring an additional 973 shares during the period. Rhumbline Advisers raised its stake in Sanara MedTech by 14.9% during the 1st quarter. Rhumbline Advisers now owns 3,714 shares of the company’s stock worth $115,000 after acquiring an additional 483 shares during the period. Finally, Salem Investment Counselors Inc. lifted its holdings in Sanara MedTech by 25.0% during the fourth quarter. Salem Investment Counselors Inc. now owns 10,897 shares of the company’s stock valued at $254,000 after purchasing an additional 2,182 shares in the last quarter. Hedge funds and other institutional investors own 8.10% of the company’s stock.

Sanara MedTech Company Profile

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.